Numinus Wellness (TSX.V: NUMI), a mental-health-care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, has joined with Optimi Health Corp.(CSE: OPTI) (OTC: OPTHF) (FRA: 8BN) to submit an all-natural psilocybin extract to Health Canada for pre-clinical trial approval. Optimi Health is the developer of a vertically integrated functional mushroom brand focused on the health and wellness sector. The submission to Health Canada marks a significant milestone in the development of the extract. The two companies submitted the application through Impact Clinical Trials Accelerator at the University of Calgary; validation studies as well as cultivation, research, and formulation have been conducted at the Health Canada-licensed Numinus lab in British Columbia, Canada. “Numinus is pleased to partner with Optimi on this important work and provide the expertise, licensed facility and specialized equipment required to quickly develop, formulate and rigorously test products derived from natural Psilocybe sources and prepare them for Health Canada submissions and approvals,” said Numinus BioScience general manager and science officer Sharan Sidhu in the press release. “We look forward to continuing our work with Optimi to develop safe, standardized and reproducible products that provide meaningful and accurate clinical trial data.”
To view the full press release, visit https://ibn.fm/oDpQJ
About Numinus Wellness Inc.
Numinus Wellness empowers people to heal and be well through the development and delivery of innovative mental health care and access to safe, evidence-based psychedelic-assisted therapies. The Numinus Wellness model — including psychedelic production, research and clinic care — is at the forefront of a transformation aimed at healing rather than managing symptoms for depression, anxiety, trauma, pain and substance abuse. Numinus is leading the integration of psychedelic-assisted therapies into mainstream clinical practice and building the foundation for a healthier society. For more information about the company, please visit www.Numinus.ca.
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.investorwire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]
InvestorWire is part of the InvestorBrandNetwork.